Objective:

To evaluate the role of laser trabeculoplasty (LTP) as a treatment option for primary open-angle glaucoma (POAG) and its implications in clinical practice, highlighting its growing significance.

Key Findings:

• LTP provides continuous pressure control and is less dependent on patient compliance compared to topical medications, which is crucial for effective glaucoma management.
• The UK healthcare policy recommends LTP as a primary treatment for newly diagnosed ocular hypertension, reflecting a shift in treatment paradigms.
• LTP has become more relevant as a first-line treatment option amidst the rise of minimally invasive glaucoma surgeries, necessitating further exploration of its long-term effectiveness.

Interpretation:

The evolving landscape of glaucoma treatment emphasizes the importance of LTP as a viable first-line option, supported by clinical evidence and changing healthcare policies.

Limitations:

• LTP does not cure glaucoma and its effects may diminish over time, and the study does not address long-term patient adherence to LTP compared to medications, nor the variability in patient responses to LTP.

Conclusion:

LTP is increasingly recognized as an effective first-line treatment for glaucoma, with supportive evidence from recent studies and policy changes encouraging its use. Ongoing research and patient education are essential for maximizing its benefits.